Your browser doesn't support javascript.
loading
Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
Allahyari, Abolghasem; Seddigh-Shamsi, Mohsen; Mahmoudi, Mahmoud; Amel Jamehdar, Saeid; Amini, Mahnaz; Mozdourian, Mahnaz; Javidarabshahi, Zahra; Eslami Hasan Abadi, Saeed; Amini, Shahram; Sedaghat, Alireza; Emadzadeh, Maryam; Moeini Nodeh, Mohammad; Rahimi, Hossein; Bari, Alireza; Mozaheb, Zahra; Kamandi, Mostafa; Ataei Azimi, Sajad; Abrishami, Mojtaba; Akbarian, Arezoo; Ataei, Parisa; Allahyari, Negin; Hasanzadeh, Sepideh; Saeedian, Neda.
Afiliación
  • Allahyari A; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Seddigh-Shamsi M; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: seddighshamsim@mums.ac.ir.
  • Mahmoudi M; Immunology research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Amel Jamehdar S; Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Amini M; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Division of Sleep Medicine, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mozdourian M; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Javidarabshahi Z; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Eslami Hasan Abadi S; Department of Medical Information, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Amini S; Faculty of Critical Care medicine, Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Sedaghat A; Faculty of Critical Care medicine, Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Emadzadeh M; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Moeini Nodeh M; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Rahimi H; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Bari A; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mozaheb Z; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Kamandi M; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ataei Azimi S; Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Abrishami M; Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Akbarian A; Department of Obstetrics and Gynecology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ataei P; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Allahyari N; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Hasanzadeh S; Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Saeedian N; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: saeediann971@mums.ac.ir.
Int Immunopharmacol ; 93: 107239, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33582019
Since SARS-CoV-2 infection is rapidly spreading all around the world, affecting many people and exhausting health care resources, therapeutic options must be quickly investigated in order to develop a safe and effective treatment. The present study was designed to evaluate the safety and efficacy of convalescent plasma (CP) for treating severe cases of COVID-19 who developed acute respiratory distress syndrome (ARDS). Among 64 confirmed cases of severe COVID-19 with ARDS in this study, 32 patients received CP besides first line treatment. Their clinical response and outcome in regard to disease severity and mortality rate were evaluated and compared with the other 32 patients in the control group who were historically matched while randomly chosen from previous patients with the same conditions except for receiving CP therapy. Analysis of the data was performed using SPSS software. Patients with plasma therapy showed improvements in their clinical outcomes including a reduction in disease severity in terms of SOFA and APACHE II scores, the length of ICU stay, need for noninvasive ventilation and intubation and also showed an increase in oxygenation. They also showed reduction in mortality which was statistically significant in less severe cases with mild or moderate ARDS. Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos